A Clinical trial to study the effect of Patha (Cissampelos pariera) in patients with painful menstruation.
Not Applicable
- Conditions
- Health Condition 1: N944- Primary dysmenorrhea
- Registration Number
- CTRI/2021/09/036512
- Lead Sponsor
- Himani
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients or parents of the young patients who agree to give written consent
patients having chief complaint of painful menses
patient suffering from primary dysmenorrhoea for more than 3 cycles
Exclusion Criteria
Patients or parents of the young patients who do not agree to give written consent.
Patient with chronic systemic illness and uterine pathology like fibroid, adenomyosis, endometriosis.
Patient with intrauterine contraceptive devices.
Patient suffering from hypothyroidism or Hyperthyroidism.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Menstruation is not painful anymore or is reduced to a substantial amount.Timepoint: 3 Months
- Secondary Outcome Measures
Name Time Method Menstruation is still painful to the same extent as before Intervention.Timepoint: 3 Months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of Cissampelos pariera contribute to dysmenorrhea pain relief?
How does Patha compare to NSAIDs in managing primary dysmenorrhea symptoms?
Are there specific biomarkers that predict response to Cissampelos pariera treatment in dysmenorrhea?
What are the potential adverse events associated with Patha (Cissampelos pariera) in clinical use?
What combination therapies involving Cissampelos pariera show promise for dysmenorrhea treatment?